These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 19131920)

  • 1. Early Barrett's carcinoma of the esophagus.
    Hölscher AH; Vallböhmer D; Bollschweiler E
    Ann Thorac Cardiovasc Surg; 2008 Dec; 14(6):347-54. PubMed ID: 19131920
    [No Abstract]   [Full Text] [Related]  

  • 2. Barrett's esophagus-emerging concepts and controversies.
    Schuchert MJ; Luketich JD
    J Surg Oncol; 2007 Mar; 95(3):185-9. PubMed ID: 17323330
    [No Abstract]   [Full Text] [Related]  

  • 3. Advanced pathology under squamous epithelium on initial EMR specimens in patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma: implications for surveillance and endotherapy management.
    Chennat J; Ross AS; Konda VJ; Lin S; Noffsinger A; Hart J; Waxman I
    Gastrointest Endosc; 2009 Sep; 70(3):417-21. PubMed ID: 19555948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endoscopic follow-up and management of Barrett's esophagus in relation to its preneoplastic potential.
    Navarro-Dourdil M; Charro-Calvillo M; Uribarrena-Amézaga R; Sebastián-Domingo JJ
    Hepatogastroenterology; 2014; 61(133):1241-5. PubMed ID: 25436290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Barrett's esophagus with high-grade dysplasia and intramucosal adenocarcinoma.
    Zehetner J; DeMeester SR
    Expert Rev Gastroenterol Hepatol; 2009 Oct; 3(5):493-8. PubMed ID: 19817671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total endoscopic eradication of Barrett's esophagus: study methodology, candidate selection, and clinical outcomes.
    Shaheen NJ; Spechler SJ
    Endoscopy; 2008 Dec; 40(12):994-9. PubMed ID: 19065482
    [No Abstract]   [Full Text] [Related]  

  • 7. Occult adenocarcinoma after esophagectomy for Barrett's high-grade dysplasia.
    Donnellan F; Harewood GC; Patchett SE
    Gastrointest Endosc; 2010 Feb; 71(2):429. PubMed ID: 20152322
    [No Abstract]   [Full Text] [Related]  

  • 8. [Limited surgical resection versus local endoscopic therapy of early cancers of the esophagogastric junction].
    von Rahden BH; Feith M; Stein HJ
    Zentralbl Chir; 2006 Apr; 131(2):97-104. PubMed ID: 16612774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling.
    Werther M; Saure C; Pahl R; Schorr F; Rüschoff J; Alles JU; Heinmöller E
    Pathol Res Pract; 2008; 204(5):285-94. PubMed ID: 18337019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgical management of Barrett's esophagus.
    Clark GW; DeMeester TR
    Ann Chir Gynaecol; 1995; 84(2):139-44. PubMed ID: 7574371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma--an American single-center experience.
    Chennat J; Konda VJ; Ross AS; de Tejada AH; Noffsinger A; Hart J; Lin S; Ferguson MK; Posner MC; Waxman I
    Am J Gastroenterol; 2009 Nov; 104(11):2684-92. PubMed ID: 19690526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Familial Barrett's adenocarcinoma.
    Melzer E; Shtoyerman R; Appelman Z; Kashtan H
    Am J Gastroenterol; 2006 Mar; 101(3):677. PubMed ID: 16542304
    [No Abstract]   [Full Text] [Related]  

  • 13. Dysplasia in Barrett's esophagus: limitations of current management strategies.
    Spechler SJ
    Am J Gastroenterol; 2005 Apr; 100(4):927-35. PubMed ID: 15784042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting surveillance in Barrett's esophagus.
    Hillman L
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1311-2. PubMed ID: 18853989
    [No Abstract]   [Full Text] [Related]  

  • 15. Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.
    Whitson MJ; Falk GW
    Gastroenterol Clin North Am; 2015 Jun; 44(2):299-315. PubMed ID: 26021196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoprevention in Barrett's oesophagus.
    Gordon V; Jankowski J
    Best Pract Res Clin Gastroenterol; 2011 Aug; 25(4-5):569-79. PubMed ID: 22122772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclooxygenase-2 in Barrett's esophagus, Barrett's adenocarcinomas, and esophageal SCC: ready for clinical trials.
    Lord RV; Danenberg KD; Danenberg PV
    Am J Gastroenterol; 1999 Aug; 94(8):2313-5. PubMed ID: 10445576
    [No Abstract]   [Full Text] [Related]  

  • 18. Histopathology of Barrett's esophagus after ablation and endoscopic mucosal resection therapy.
    Odze RD; Lauwers GY
    Endoscopy; 2008 Dec; 40(12):1008-15. PubMed ID: 19065484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoprevention of adenocarcinoma associated with Barrett's esophagus: potential options.
    Neumann H; Mönkemüller K; Vieth M; Malfertheiner P
    Dig Dis; 2009; 27(1):18-23. PubMed ID: 19439956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus.
    Kastelein F; Spaander MC; Biermann K; Steyerberg EW; Kuipers EJ; Bruno MJ;
    Gastroenterology; 2011 Dec; 141(6):2000-8; quiz e13-4. PubMed ID: 21878200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.